Proinflammatory mediators in fibromyalgia syndrome and their modulation by a multimodal therapeutic program
- Conditions
- R52.2Other chronic pain
- Registration Number
- DRKS00030753
- Lead Sponsor
- Klinik für Physikalische Medizin und Rehabilitation
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Female
- Target Recruitment
- 174
diagnosis of fibromyalgia according to ACR criteria (patients)
No pain in the last four weeks before participation in the study (healthy subjects)
participation in the day clinic focus on osteoarthritis, back pain or osteoporosis of the Clinic and Polyclinic for Physical Medicine and Rehabilitation and continuous pain VAS>3/ 10 on the visual analog scale (VAS) from 0-10 for more than 3 months (patient control group)
maturity
willingness to give a blood sample as part of the study
wllingness to refrain from taking NSAIDs and COX inhibitors from 1 week prior to and during the observation period
no intake of paracetamol and metamizole up to 3 days before the blood samples (patient diary)
Age under 18 years
lack of compliance
Pregnancy or breastfeeding period (anamnestic clarification according to CPMP/ICH/286/95)
diabetes mellitus requiring insulin
surgery in the last 3 months
severe heart disease
severe lung diseases
severe kidney disease
chronic inflammatory diseases
endocrine disorders
diseases that, due to their severity, coupe an assessment of the quality of life limitations caused by fibromyalgia
schizophrenia, dementia
severe coagulation disorders
immunosuppression
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method eicosanoid levels
- Secondary Outcome Measures
Name Time Method cytokine levels, results of FIQ, SF-36, HADS and PHQ4